title: Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
abstract: Multiple myeloma (MM) is the uncontrolled proliferation of plasma cells with variable amounts of production of immunoglobulins or their chains. Acute renal failure can be a symptom of MM, and it is sometimes its form of presentation. Circulating free light chains (FLC) could lead to renal failure due to their intratubular precipitation, causing a cast nephropathy. The treatment of myeloma, adequate hydration and the removal of FLC by apheresis techniques are currently the treatments that are accepted for this disease. Several apheresis techniques have been attempted for the removal of FLC, with long haemodialysis sessions with filters for the removal of these light chains (high cut-off filters) being proposed as the most effective treatment for myeloma nephropathy.
  
  
  METHODS
  We report 5 cases of myeloma nephropathy: three had cast nephropathy (CN) diagnosed by renal biopsy and the other two had a high probability of CN (FLC levels >500 mg/l). They were treated with long haemodialysis sessions with a high cut-off membrane. All patients had suffered acute renal failure; four required renal replacement therapy and one patient had advanced renal failure. In all patients, FLC levels were very high. They received specific treatment for myeloma in addition to high cut-off haemodialysis until they achieved FLC levels of <500 mg/l.
  
  
  RESULTS
  Four of the five patients recovered renal function, and became independent of dialysis. The progression time for myeloma from the time the first symptoms appeared varied (1-6 months). The number of treatment sessions ranged from 8-16. The patient with the longest progression time required more sessions and did not recover renal function.
  
  
  CONCLUSIONS
  Long haemodialysis sessions with high cut-off filters in addition to specific myeloma chemotherapy seems to be an effective treatment for acute renal failure due to myeloma nephropathy. The early initiation of treatment could be a determining factor for the response.
authors.affiliation: Unidad de Nefrología, Complejo Hospitalario de Jaén, Spain. jborregueroh@senefro.org
authors.forename: Josefa
authors.initials: J
authors.lastname: Borrego-Hinojosa
authors.forename: M Pilar
authors.initials: MP
authors.lastname: Pérez-del Barrio
authors.forename: M del Mar
authors.initials: Mdel M
authors.lastname: Biechy-Baldan
authors.forename: Enoc
authors.initials: E
authors.lastname: Merino-García
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Sánchez-Perales
authors.forename: M José
authors.initials: MJ
authors.lastname: García-Cortés
authors.forename: Esther
authors.initials: E
authors.lastname: Ocaña-Pérez
authors.forename: Patricia
authors.initials: P
authors.lastname: Gutiérrez-Rivas
authors.forename: Antonio
authors.initials: A
authors.lastname: Liébana-Cañada
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000209:etiology* / Q000628:therapy*; D000368:Aged; D005260:Female; D005374:Filtration / Q000295:instrumentation; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications*; D006435:Renal Dialysis / Q000295:instrumentation* / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D007147:Immunoglobulin Light Chains